Thus, the two quantitative fluorescence immunohistochemistry platforms were highly consistent in identifying clinically relevant sub-populations of patients with low levels of Nuc-pYStat5 at increased risk of breast cancer recurrence using data-driven cutpoints to dichotomize marker levels. This evidence concerns the gene NUCB1 and breast carcinoma.